A dose range study on FK 037 in bacterial pneumonia

Rinzo Soejima; Yoshihito Niki; Niro Okimoto; Osamu Moriya; Hitoshi Nakano; Kenjiro Kikuchi; Akira Saito; Ichiro Nakayama; Masumi Tomizawa; Kazuki Konishi; Kazuo Obara; Masashi Tamura; Akira Watanabe; Hiroshi Takahashi; Shigeo Takizawa; Mikae Nakamura; Kohya Shiba; Osamu Sakai; Kazuhisa Okada; Hiroichi Tanimoto; Kazuo Obara; Tetsuo Okamura; Kaoru Shimada; Yasuyuki Sano; Norihisa Akiyama; Yasuko Tanaka; Takashi Inamatsu; Hiroyuki Kobayashi; Susumu Sakayori; Hiroshi Miura; Jingoro Shimada; Seiji Hori; Fumio Matsumoto; Takeo Imai; Kouji Yoshikawa; Shigeki Odagiri; Yoshihiro Hirai; Norio Kikuchi; Yasutoshi Suzuki; Osamu Sekine; Nobuki Aoki; Toshihiko Takeuchi; Yasuo Yamada; Atsushi Nakamura; Toshinobu Yamamoto; Hidekazu Hanaki; Makoto Kawakami; Shinji Takeyama; Ikuji Usami; Hidekazu Kuroki; Fumio Miki; Nobuhiro Narita; Keiichi Mikasa; Masayoshi Sawaki; Toshiharu Matsushima; Makoto Kimura; Takao Sasaki; Yuji Sugimoto; Ikuo Matsumoto; Jiro Takahara; Jiro Fujita; Masaru Kamei; Yoshiro Sawae; Kaoru Okada; Koji Takaki; Nobuyuki Shimono; Hiroyasu Misumi; Kotaro Oizumi; Yoichiro Ichikawa; Naoto Tokunaga; Hozumi Yamada; Osamu Kato; Kohei Hara; Shigeru Kohno; Hironobu Koga; Mitsuo Kaku; Kazunori Tomono; Sadahiro Asai; Naofumi Suyama; Jun Araki; Hideo Mashimoto; Rokushi Oka; Hidenori Sugiyama; Koichi Watanabe; Keizo Matsumoto; Hiroshi Watanabe; Akemi Ohmori; Moritoshi Akiyama; Yoshiaki Utsunomiya; Kazunori Oishi; Tsuyoshi Nagatake; Hirofumi Tanaka; Hidehiko Hirose; Masakazu Takasugi; Atsushi Saito; Jun Inatome; Hiroshi Fukuhara; Yuei Irabu; Keisuke Sunakawa

doi:10.11250/chemotherapy1953.42.1143

A dose range study on FK 037 in bacterial pneumonia

Rinzo Soejima, Yoshihito Niki, Niro Okimoto, Osamu Moriya, Hitoshi Nakano, Kenjiro Kikuchi, Akira Saito, Ichiro Nakayama, Masumi Tomizawa, Kazuki Konishi, Kazuo Obara, Masashi Tamura, Akira Watanabe, Hiroshi Takahashi, Shigeo Takizawa, Mikae Nakamura, Kohya Shiba, Osamu Sakai, Kazuhisa Okada, Hiroichi TanimotoKazuo Obara, Tetsuo Okamura, Kaoru Shimada, Yasuyuki Sano, Norihisa Akiyama, Yasuko Tanaka, Takashi Inamatsu, Hiroyuki Kobayashi, Susumu Sakayori, Hiroshi Miura, Jingoro Shimada, Seiji Hori, Fumio Matsumoto, Takeo Imai, Kouji Yoshikawa, Shigeki Odagiri, Yoshihiro Hirai, Norio Kikuchi, Yasutoshi Suzuki, Osamu Sekine, Nobuki Aoki, Toshihiko Takeuchi, Yasuo Yamada, Atsushi Nakamura, Toshinobu Yamamoto, Hidekazu Hanaki, Makoto Kawakami, Shinji Takeyama, Ikuji Usami, Hidekazu Kuroki, Fumio Miki, Nobuhiro Narita, Keiichi Mikasa, Masayoshi Sawaki, Toshiharu Matsushima, Makoto Kimura, Takao Sasaki, Yuji Sugimoto, Ikuo Matsumoto, Jiro Takahara, Jiro Fujita, Masaru Kamei, Yoshiro Sawae, Kaoru Okada, Koji Takaki, Nobuyuki Shimono, Hiroyasu Misumi, Kotaro Oizumi, Yoichiro Ichikawa, Naoto Tokunaga, Hozumi Yamada, Osamu Kato, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Kazunori Tomono, Sadahiro Asai, Naofumi Suyama, Jun Araki, Hideo Mashimoto, Rokushi Oka, Hidenori Sugiyama, Koichi Watanabe, Keizo Matsumoto, Hiroshi Watanabe, Akemi Ohmori, Moritoshi Akiyama, Yoshiaki Utsunomiya, Kazunori Oishi, Tsuyoshi Nagatake, Hirofumi Tanaka, Hidehiko Hirose, Masakazu Takasugi, Atsushi Saito, Jun Inatome, Hiroshi Fukuhara, Yuei Irabu, Keisuke Sunakawa

研究成果: Article › 査読

15 被引用数 (Scopus)

抄録

A dose range study on FK 037, a parenteral cephalosporin, was conducted in patients with bacterial pneumonia. 1) Patients with bacterial pneumonia were intravenously infused with FK 037 at a dose of 0.5 g (0.5 g group), 1.0 g (1.0 g group) or 2.0 g (2.0 g group), twice daily, for 14 days as a rule. Of 95 patients, 82 were assessed for the efficacy and clinical usefulness of the drug, and 93 patients for the safety of the drug. 2) The clinical efficacy rate was 85.2% (23/27) in the 0.5 g group, 90.0% (27/30) in the 1.0 g group and 92.0% (23/25) in the 2.0 g group. 3) In the bacteriological evaluation, the eradication rate was 91.7% (11/12) in the 0.5 g group, 85.7% (6/7) in the 1.0 g group and 90.9% (10/11) in the 2.0 g group. 4) As for side effects, diarrhea was observed in only 1 patient in the 1.0 g group. 5) Abnormal changes in laboratory tests were observed in 6 patients (19.4%) in the 0.5 g group, 11 patients (34.4%) in the 1.0 g group and 5 patients (17.9%) in the 2.0 g group. None of the abnormal laboratory findings was serious or associated with clinical symptoms. 6) Clinical usefulness rates were 81.5% (22/27), 86.7% (26/30) and 92.0% (23/25) in the 0.5 g, 1.0 g and 2.0 g group, respectively. We considered that a twice daily dose of 1.0 g of FK 037 is the appropiate clinical dosase for bacterial pneumonia.

本文言語	English
ページ（範囲）	1143-1161
ページ数	19
ジャーナル	Chemotherapy
巻	42
号	10
DOI	https://doi.org/10.11250/chemotherapy1953.42.1143
出版ステータス	Published - 1994
外部発表	はい

ASJC Scopus subject areas

薬理学（医学）
感染症
薬理学
創薬
腫瘍学

UN SDG

この成果は、次の持続可能な開発目標に貢献しています

文献へのアクセス

10.11250/chemotherapy1953.42.1143

他のファイルとリンク

Scopusの出版物のリンク

引用スタイル

Soejima, R., Niki, Y., Okimoto, N., Moriya, O., Nakano, H., Kikuchi, K., Saito, A., Nakayama, I., Tomizawa, M., Konishi, K., Obara, K., Tamura, M., Watanabe, A., Takahashi, H., Takizawa, S., Nakamura, M., Shiba, K., Sakai, O., Okada, K., ... Sunakawa, K. (1994). A dose range study on FK 037 in bacterial pneumonia. Chemotherapy, 42(10), 1143-1161. https://doi.org/10.11250/chemotherapy1953.42.1143

Soejima, R, Niki, Y, Okimoto, N, Moriya, O, Nakano, H, Kikuchi, K, Saito, A, Nakayama, I, Tomizawa, M, Konishi, K, Obara, K, Tamura, M, Watanabe, A, Takahashi, H, Takizawa, S, Nakamura, M, Shiba, K, Sakai, O, Okada, K, Tanimoto, H, Obara, K, Okamura, T, Shimada, K, Sano, Y, Akiyama, N, Tanaka, Y, Inamatsu, T, Kobayashi, H, Sakayori, S, Miura, H, Shimada, J, Hori, S, Matsumoto, F, Imai, T, Yoshikawa, K, Odagiri, S, Hirai, Y, Kikuchi, N, Suzuki, Y, Sekine, O, Aoki, N, Takeuchi, T, Yamada, Y, Nakamura, A, Yamamoto, T, Hanaki, H, Kawakami, M, Takeyama, S, Usami, I, Kuroki, H, Miki, F, Narita, N, Mikasa, K, Sawaki, M, Matsushima, T, Kimura, M, Sasaki, T, Sugimoto, Y, Matsumoto, I, Takahara, J, Fujita, J, Kamei, M, Sawae, Y, Okada, K, Takaki, K, Shimono, N, Misumi, H, Oizumi, K, Ichikawa, Y, Tokunaga, N, Yamada, H, Kato, O, Hara, K, Kohno, S, Koga, H, Kaku, M, Tomono, K, Asai, S, Suyama, N, Araki, J, Mashimoto, H, Oka, R, Sugiyama, H, Watanabe, K, Matsumoto, K, Watanabe, H, Ohmori, A, Akiyama, M, Utsunomiya, Y, Oishi, K, Nagatake, T, Tanaka, H, Hirose, H, Takasugi, M, Saito, A, Inatome, J, Fukuhara, H, Irabu, Y & Sunakawa, K 1994, 'A dose range study on FK 037 in bacterial pneumonia', Chemotherapy, vol. 42, no. 10, pp. 1143-1161. https://doi.org/10.11250/chemotherapy1953.42.1143

@article{27c5d65115684f89b4c0f40a03fec2a3,

title = "A dose range study on FK 037 in bacterial pneumonia",

abstract = "A dose range study on FK 037, a parenteral cephalosporin, was conducted in patients with bacterial pneumonia. 1) Patients with bacterial pneumonia were intravenously infused with FK 037 at a dose of 0.5 g (0.5 g group), 1.0 g (1.0 g group) or 2.0 g (2.0 g group), twice daily, for 14 days as a rule. Of 95 patients, 82 were assessed for the efficacy and clinical usefulness of the drug, and 93 patients for the safety of the drug. 2) The clinical efficacy rate was 85.2% (23/27) in the 0.5 g group, 90.0% (27/30) in the 1.0 g group and 92.0% (23/25) in the 2.0 g group. 3) In the bacteriological evaluation, the eradication rate was 91.7% (11/12) in the 0.5 g group, 85.7% (6/7) in the 1.0 g group and 90.9% (10/11) in the 2.0 g group. 4) As for side effects, diarrhea was observed in only 1 patient in the 1.0 g group. 5) Abnormal changes in laboratory tests were observed in 6 patients (19.4%) in the 0.5 g group, 11 patients (34.4%) in the 1.0 g group and 5 patients (17.9%) in the 2.0 g group. None of the abnormal laboratory findings was serious or associated with clinical symptoms. 6) Clinical usefulness rates were 81.5% (22/27), 86.7% (26/30) and 92.0% (23/25) in the 0.5 g, 1.0 g and 2.0 g group, respectively. We considered that a twice daily dose of 1.0 g of FK 037 is the appropiate clinical dosase for bacterial pneumonia.",

keywords = "FK 037",

author = "Rinzo Soejima and Yoshihito Niki and Niro Okimoto and Osamu Moriya and Hitoshi Nakano and Kenjiro Kikuchi and Akira Saito and Ichiro Nakayama and Masumi Tomizawa and Kazuki Konishi and Kazuo Obara and Masashi Tamura and Akira Watanabe and Hiroshi Takahashi and Shigeo Takizawa and Mikae Nakamura and Kohya Shiba and Osamu Sakai and Kazuhisa Okada and Hiroichi Tanimoto and Kazuo Obara and Tetsuo Okamura and Kaoru Shimada and Yasuyuki Sano and Norihisa Akiyama and Yasuko Tanaka and Takashi Inamatsu and Hiroyuki Kobayashi and Susumu Sakayori and Hiroshi Miura and Jingoro Shimada and Seiji Hori and Fumio Matsumoto and Takeo Imai and Kouji Yoshikawa and Shigeki Odagiri and Yoshihiro Hirai and Norio Kikuchi and Yasutoshi Suzuki and Osamu Sekine and Nobuki Aoki and Toshihiko Takeuchi and Yasuo Yamada and Atsushi Nakamura and Toshinobu Yamamoto and Hidekazu Hanaki and Makoto Kawakami and Shinji Takeyama and Ikuji Usami and Hidekazu Kuroki and Fumio Miki and Nobuhiro Narita and Keiichi Mikasa and Masayoshi Sawaki and Toshiharu Matsushima and Makoto Kimura and Takao Sasaki and Yuji Sugimoto and Ikuo Matsumoto and Jiro Takahara and Jiro Fujita and Masaru Kamei and Yoshiro Sawae and Kaoru Okada and Koji Takaki and Nobuyuki Shimono and Hiroyasu Misumi and Kotaro Oizumi and Yoichiro Ichikawa and Naoto Tokunaga and Hozumi Yamada and Osamu Kato and Kohei Hara and Shigeru Kohno and Hironobu Koga and Mitsuo Kaku and Kazunori Tomono and Sadahiro Asai and Naofumi Suyama and Jun Araki and Hideo Mashimoto and Rokushi Oka and Hidenori Sugiyama and Koichi Watanabe and Keizo Matsumoto and Hiroshi Watanabe and Akemi Ohmori and Moritoshi Akiyama and Yoshiaki Utsunomiya and Kazunori Oishi and Tsuyoshi Nagatake and Hirofumi Tanaka and Hidehiko Hirose and Masakazu Takasugi and Atsushi Saito and Jun Inatome and Hiroshi Fukuhara and Yuei Irabu and Keisuke Sunakawa",

year = "1994",

doi = "10.11250/chemotherapy1953.42.1143",

language = "English",

volume = "42",

pages = "1143--1161",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "10",

}

TY - JOUR

T1 - A dose range study on FK 037 in bacterial pneumonia

AU - Soejima, Rinzo

AU - Niki, Yoshihito

AU - Okimoto, Niro

AU - Moriya, Osamu

AU - Nakano, Hitoshi

AU - Kikuchi, Kenjiro

AU - Saito, Akira

AU - Nakayama, Ichiro

AU - Tomizawa, Masumi

AU - Konishi, Kazuki

AU - Obara, Kazuo

AU - Tamura, Masashi

AU - Watanabe, Akira

AU - Takahashi, Hiroshi

AU - Takizawa, Shigeo

AU - Nakamura, Mikae

AU - Shiba, Kohya

AU - Sakai, Osamu

AU - Okada, Kazuhisa

AU - Tanimoto, Hiroichi

AU - Obara, Kazuo

AU - Okamura, Tetsuo

AU - Shimada, Kaoru

AU - Sano, Yasuyuki

AU - Akiyama, Norihisa

AU - Tanaka, Yasuko

AU - Inamatsu, Takashi

AU - Kobayashi, Hiroyuki

AU - Sakayori, Susumu

AU - Miura, Hiroshi

AU - Shimada, Jingoro

AU - Hori, Seiji

AU - Matsumoto, Fumio

AU - Imai, Takeo

AU - Yoshikawa, Kouji

AU - Odagiri, Shigeki

AU - Hirai, Yoshihiro

AU - Kikuchi, Norio

AU - Suzuki, Yasutoshi

AU - Sekine, Osamu

AU - Aoki, Nobuki

AU - Takeuchi, Toshihiko

AU - Yamada, Yasuo

AU - Nakamura, Atsushi

AU - Yamamoto, Toshinobu

AU - Hanaki, Hidekazu

AU - Kawakami, Makoto

AU - Takeyama, Shinji

AU - Usami, Ikuji

AU - Kuroki, Hidekazu

AU - Miki, Fumio

AU - Narita, Nobuhiro

AU - Mikasa, Keiichi

AU - Sawaki, Masayoshi

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Sasaki, Takao

AU - Sugimoto, Yuji

AU - Matsumoto, Ikuo

AU - Takahara, Jiro

AU - Fujita, Jiro

AU - Kamei, Masaru

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Takaki, Koji

AU - Shimono, Nobuyuki

AU - Misumi, Hiroyasu

AU - Oizumi, Kotaro

AU - Ichikawa, Yoichiro

AU - Tokunaga, Naoto

AU - Yamada, Hozumi

AU - Kato, Osamu

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Koga, Hironobu

AU - Kaku, Mitsuo

AU - Tomono, Kazunori

AU - Asai, Sadahiro

AU - Suyama, Naofumi

AU - Araki, Jun

AU - Mashimoto, Hideo

AU - Oka, Rokushi

AU - Sugiyama, Hidenori

AU - Watanabe, Koichi

AU - Matsumoto, Keizo

AU - Watanabe, Hiroshi

AU - Ohmori, Akemi

AU - Akiyama, Moritoshi

AU - Utsunomiya, Yoshiaki

AU - Oishi, Kazunori

AU - Nagatake, Tsuyoshi

AU - Tanaka, Hirofumi

AU - Hirose, Hidehiko

AU - Takasugi, Masakazu

AU - Saito, Atsushi

AU - Inatome, Jun

AU - Fukuhara, Hiroshi

AU - Irabu, Yuei

AU - Sunakawa, Keisuke

PY - 1994

Y1 - 1994

N2 - A dose range study on FK 037, a parenteral cephalosporin, was conducted in patients with bacterial pneumonia. 1) Patients with bacterial pneumonia were intravenously infused with FK 037 at a dose of 0.5 g (0.5 g group), 1.0 g (1.0 g group) or 2.0 g (2.0 g group), twice daily, for 14 days as a rule. Of 95 patients, 82 were assessed for the efficacy and clinical usefulness of the drug, and 93 patients for the safety of the drug. 2) The clinical efficacy rate was 85.2% (23/27) in the 0.5 g group, 90.0% (27/30) in the 1.0 g group and 92.0% (23/25) in the 2.0 g group. 3) In the bacteriological evaluation, the eradication rate was 91.7% (11/12) in the 0.5 g group, 85.7% (6/7) in the 1.0 g group and 90.9% (10/11) in the 2.0 g group. 4) As for side effects, diarrhea was observed in only 1 patient in the 1.0 g group. 5) Abnormal changes in laboratory tests were observed in 6 patients (19.4%) in the 0.5 g group, 11 patients (34.4%) in the 1.0 g group and 5 patients (17.9%) in the 2.0 g group. None of the abnormal laboratory findings was serious or associated with clinical symptoms. 6) Clinical usefulness rates were 81.5% (22/27), 86.7% (26/30) and 92.0% (23/25) in the 0.5 g, 1.0 g and 2.0 g group, respectively. We considered that a twice daily dose of 1.0 g of FK 037 is the appropiate clinical dosase for bacterial pneumonia.

AB - A dose range study on FK 037, a parenteral cephalosporin, was conducted in patients with bacterial pneumonia. 1) Patients with bacterial pneumonia were intravenously infused with FK 037 at a dose of 0.5 g (0.5 g group), 1.0 g (1.0 g group) or 2.0 g (2.0 g group), twice daily, for 14 days as a rule. Of 95 patients, 82 were assessed for the efficacy and clinical usefulness of the drug, and 93 patients for the safety of the drug. 2) The clinical efficacy rate was 85.2% (23/27) in the 0.5 g group, 90.0% (27/30) in the 1.0 g group and 92.0% (23/25) in the 2.0 g group. 3) In the bacteriological evaluation, the eradication rate was 91.7% (11/12) in the 0.5 g group, 85.7% (6/7) in the 1.0 g group and 90.9% (10/11) in the 2.0 g group. 4) As for side effects, diarrhea was observed in only 1 patient in the 1.0 g group. 5) Abnormal changes in laboratory tests were observed in 6 patients (19.4%) in the 0.5 g group, 11 patients (34.4%) in the 1.0 g group and 5 patients (17.9%) in the 2.0 g group. None of the abnormal laboratory findings was serious or associated with clinical symptoms. 6) Clinical usefulness rates were 81.5% (22/27), 86.7% (26/30) and 92.0% (23/25) in the 0.5 g, 1.0 g and 2.0 g group, respectively. We considered that a twice daily dose of 1.0 g of FK 037 is the appropiate clinical dosase for bacterial pneumonia.

KW - FK 037

UR - http://www.scopus.com/inward/record.url?scp=0027987775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027987775&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.42.1143

DO - 10.11250/chemotherapy1953.42.1143

M3 - Article

AN - SCOPUS:0027987775

VL - 42

SP - 1143

EP - 1161

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 10

ER -

A dose range study on FK 037 in bacterial pneumonia

抄録

ASJC Scopus subject areas

UN SDG

文献へのアクセス

他のファイルとリンク

フィンガープリント

引用スタイル